Rare Diseases And Beyond: FDA Seeks Input On Establishing Clinical Trial Networks
Executive Summary
US FDA is looking for advice on how to design a clinical trial network to complete the third component of its Rare Disease Cures Accelerator Program, but it also wants advice on clinical trial networks more broadly. The rare disease network will need to be global given the more limited patient populations, the agency said.
You may also be interested in...
Clinical Outcome Assessments To Be Developed Under US FDA Grants
The projects could help streamline rare disease drug development, along with the Rare Disease Cures Accelerator.
Patent Settlements and Medicare Negotiation: What Leverage Does Pharma Have To ‘Game’ Price Reform?
Brand drug companies might be able to use patent settlements with generic and biosimilar makers to get out of the drug price negotiations that will be created under the US legislation nearing enactment, but sponsors could run into regulatory and antitrust obstacles.